Protect Against 

Leprosy

 AAHI: 

  • Developed an adjuvanted leprosy vaccine candidate, LepVax, proven to be safe and immunogenic in a phase 1 clinical trials. A Phase 1/ 2 clinical trial is anticipated to begin soon in Brazil. 

Leprosy, or Hansen's Disease, is caused by a slow-growing bacteria, Mycobacterium leprae, is primarily transmitted by droplets from the nose and mouth during prolonged close contact with untreated patients.

If leprosy is left untreated, it results in physical deformity such as skin lesions, loss of eyebrows and eyelashes, and erosion of fingers and toes, with accompanying nerve damage. The physical deformities lead to stigmatization and discrimination, perpetuating mental health issues and handcuffing contributions to society. 

A TREATABLE DISEASE

Current leprosy treatments entail lengthy and expensive multidrug therapy that requires continual monitoring and cannot remedy existing physical or nerve damage. The yearlong treatment regimen consists of dapsone, rifampicin, and clofazimine and is most effective with early diagnosis. 

Leprosy prevention efforts are focused on interrupting human transmission through early case detection and treatment. But such efforts have proven to be ineffective. The WHO recommends administering preventive chemotherapy to household and social contacts of patients.

Of the 200,000 reported cases, almost 15,000 of those cases are children. Leprosy is a neglected tropical disease most common in Brazil, India, and Indonesia, but it ultimately is reported from all six WHO regions of the world. It is a neglected tropical disease that burdens poor and rural areas and perpetuates poverty. 

CONTENTS

3. What AAHI Does About It

LepVax combines an innovative fusion protein, LEP-F1, with AAHI's GLA-SE adjuvant formulation.

  • Designed to provide protection to families or other close contacts of leprosy patients in leprosy-endemic regions.  
  • Simple and inexpensive to manufacture at large scale
  • Safe and well-tolerated in a Phase 1 clinical trial conducted in collaboration with the American Leprosy Mission (NCT03302897).

LepVax is anticipated to be evaluated in both healthy adults and leprosy patients in Brazil in a Phase 1/ 2 clinical trial sponsored by FioCruz (NCT03947437).

Latest News